Matthew S Davids, Alen Ostojic, Susana Wargo, Moana Hodari, Jiefen Munley, Richard Hermann. "Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study." Blood, 2025. doi:10.1182/blood-2025-3912